The intersection of the two complementary fields of preventive cardiology and integrative cardiology: A fellow's voice

Cheung, Brian

doi:10.1016/j.ajpc.2022.100433

Cited by 2 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nutraceuticals used to treat dyslipidemia have been gaining popularity with both patients and clinicians [12]. They can be used in patients who have SAMS or other side effects from statins.…”

Section: Discussionmentioning

confidence: 99%

“…Integrative cardiologists are uniquely equipped to guide this emerging field of medicine and the use of nutraceuticals in the management of dyslipidemia. There is a potential opportunity to reduce ASCVD risk and to promote cardiovascular prevention [12]. Clinicians can help patients obtain accurate information and continue to generate the science to support the clinical use of nutraceuticals.…”

Section: Discussionmentioning

confidence: 99%

“…More patients are actively seeking integrative therapies, including nutraceuticals, from clinicians with expertise in integrative cardiology [12]. The estimated global prevalence of dietary supplement and nutraceutical use in patients with cardiovascular disease is 36% [13].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia

Cheung

Sikand

Dineen

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Dyslipidemia is a treatable risk factor for atherosclerotic cardiovascular disease that can be addressed through lifestyle changes and/or lipid-lowering therapies. Adherence to statins can be a clinical challenge in some patients due to statin-associated muscle symptoms and other side effects. There is a growing interest in integrative cardiology and nutraceuticals in the management of dyslipidemia, as some patients desire or are actively seeking a more natural approach. These agents have been used in patients with and without established atherosclerotic cardiovascular disease. We provide an updated review of the evidence on many new and emerging nutraceuticals. We describe the mechanism of action, lipid-lowering effects, and side effects of many nutraceuticals, including red yeast rice, bergamot and others.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia

Cheung

Sikand

Dineen

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, they are associated with a high incidence of statin-associated muscle symptoms such as rhabdomyolysis, which may contribute to decreased adherence [ 38 ]. Therefore, there is an increasing need for dietary supplements and nutraceuticals (nutraceuticals) as integrative therapy in combination with pharmaceuticals or as adjunctive therapy when LDL-C does not reach target levels with drug therapy [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

Inhibitory effect of trans-tiliroside on very low-density lipoprotein secretion in HepG2 cells and mouse liver

Nagatomo,

Kohno,

Kawakami

et al. 2023

J Nat Med

View full text Add to dashboard Cite

An acylated flavonol glycoside, trans-tiliroside (1), is found in certain parts of different herbs, including the seeds of Rosa canina (Rosaceae). Previous studies on compound 1 have focused on triglyceride (TG) metabolism, including its anti-obesity and intracellular TG reduction effects. In the present study, the effects of compound 1 on cholesterol (CHO) metabolism were investigated using human hepatocellular carcinoma-derived HepG2 cells and mice. Compound 1 decreased CHO secretion in HepG2 cells, which was enhanced by mevalonate in a concentration-dependent manner and decreased the secretion of apoprotein B (apoB)-100, a marker of very low-density lipoprotein (VLDL). Compound 1 also inhibited the activity of microsomal triglyceride transfer proteins, which mediate VLDL formation from cholesterol and triglycerides in the liver. In vivo, compound 1 inhibited the accumulation of Triton WR-1339-induced TG in the blood of fasted mice and maintained low levels of apoB-100. These results suggest that compound 1 inhibits the secretion of CHO as VLDL from the liver and has the potential for use for the prevention of dyslipidemia. Graphical abstract

show abstract

The intersection of the two complementary fields of preventive cardiology and integrative cardiology: A fellow's voice

Cited by 2 publications

References 7 publications

Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia

Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia

Inhibitory effect of trans-tiliroside on very low-density lipoprotein secretion in HepG2 cells and mouse liver

Contact Info

Product

Resources

About